Mirikizumab to heal intestinal damage in Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This trial tests if mirikizumab can reduce deep inflammation in the intestine walls in people with active Crohn's disease. It may help heal damage that shows up on an MRI scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with Crohn's disease and have active symptoms (like more than 3 loose stools a day or belly pain).
- An MRI shows significant inflammation or damage inside the bowel wall.
- You have not taken a medicine like mirikizumab (a type of anti-IL23 treatment) before.
- You have not tried more than one type of advanced Crohn's treatment (like certain biologics or JAK inhibitors).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
This trial tests a medication called Mirikizumab for adults over 60 with moderate to severe Crohn's disease or ulcerative colitis. It aims to see if the drug is safe and effective for older adults with these conditions.
This study tests mirikizumab to reduce inflammation and symptoms in children with Crohn’s disease that is currently active. It may help if your Crohn’s has not improved enough (or stopped working) with at least one other Crohn’s medicine.
This study tests a medication called mirikizumab to see if it can help people with Crohn's disease who have narrowing (strictures) in the small intestine caused by inflammation. The goal is to improve symptoms like belly pain after eating and to possibly reduce the narrowing without needing surgery.
This trial is testing multiple new drugs for people with moderate to severe ulcerative colitis or Crohn's disease who have not had success with at least one standard treatment. The goal is to find a better option that can help control symptoms and inflammation.
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
Hear when a new Crohn Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.